Your browser doesn't support javascript.
loading
HER2-low status may predict poor neoadjuvant chemotherapy response in HR-negative breast cancer: a real-world multicenter study.
Xu, Weiwei; Jiang, Yunshan; Xu, Lingyun; Li, Changwen; Wang, Ji; Liu, Zhao; Xue, Dandan; Gu, Yanlin; Zhong, Zhaoyun; He, Shiqing; Wang, Shui; Zhou, Wenbin; Pan, Hong.
Afiliación
  • Xu W; Department of Breast Surgery, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
  • Jiang Y; Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Jiangsu Collaborative Innovation Center for Cancer Personalized Medicine, School of Public Health, Nanjing Medical University, Nanjing, China.
  • Xu L; Department of Breast Surgery, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
  • Li C; Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Jiangsu Collaborative Innovation Center for Cancer Personalized Medicine, School of Public Health, Nanjing Medical University, Nanjing, China.
  • Wang J; Department of Breast Surgery, The Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, Changzhou, China.
  • Liu Z; Department of Breast Surgery, Xuzhou Central Hospital, XuZhou Clinical School of Xuzhou Medical University, Xuzhou, China.
  • Xue D; Department of Breast Surgery, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
  • Gu Y; Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Jiangsu Collaborative Innovation Center for Cancer Personalized Medicine, School of Public Health, Nanjing Medical University, Nanjing, China.
  • Zhong Z; Department of Thyroid and Breast Surgery, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
  • He S; Department of Thyroid and Breast Surgery, The Affiliated Hospital of Nantong University, Nantong, China.
  • Wang S; Department of Thyroid and Breast Surgery, The Second Affiliated Hospital of Soochow University, Suzhou, China.
  • Zhou W; Department of Breast Surgery, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
  • Pan H; Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Jiangsu Collaborative Innovation Center for Cancer Personalized Medicine, School of Public Health, Nanjing Medical University, Nanjing, China.
Jpn J Clin Oncol ; 53(6): 463-471, 2023 Jun 01.
Article en En | MEDLINE | ID: mdl-36757139
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Neoplasias de la Mama Triple Negativas Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Revista: Jpn J Clin Oncol Año: 2023 Tipo del documento: Article País de afiliación: China
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Neoplasias de la Mama Triple Negativas Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Revista: Jpn J Clin Oncol Año: 2023 Tipo del documento: Article País de afiliación: China